Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2023.06.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The procedural success of primary angioplasty in a tertiary care center in Pakistan.
Pak J Med Sci
December 2024
Madiha Iqbal, FCPS (Cardiology) Assistant Professor of Cardiology, King Edward Medical University, Lahore, Pakistan.
Article Synopsis
- The study aimed to assess the effectiveness of primary angioplasty by measuring TIMI flow and myocardial blush grades (MBG) before and after the procedure.
- Conducted on 106 patients at the Punjab Institute of Cardiology, the study found that 65% showed improved TIMI flow and 55% improved MBG, with quicker balloon insertion time linked to better outcomes.
- The conclusion highlights that while primary angioplasty is effective for restoring blood flow in heart attacks, there is still room for improvement, especially for patients presenting late.
Comparison of the effects on coagulation function and safety of bivalirudin and heparin in patients undergoing percutaneous coronary intervention: A randomized trial.
Medicine (Baltimore)
November 2024
Department of Cardiovascular Medicine, Datong Third People's Hospital, Datong, China.
Background: To analyze the effects on coagulation function and safety of bivalirudin and heparin in patients undergoing percutaneous coronary intervention (PCI) and provide clinical evidence for their application.
Methods: A total of 42 patients with coronary heart disease undergoing PCI treatment from July 2019 to January 2022 at Datong Third People's Hospital in China were divided into 2 groups: the bivalirudin group and the heparin group. The former received perioperative administration of bivalirudin, while the latter received heparin.
Cardiogenic shock.
Lancet
November 2024
Leipzig Heart Science, Leipzig, Germany; Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. Electronic address:
Article Synopsis
Breaking Down Cardiogenic Shock: An Analytical Reflection on the DanGer-SHOCK and ECLS-SHOCK Trials.
Am J Cardiol
November 2024
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy.
Article Synopsis
- Mechanical circulatory support devices, especially the microaxial flow pump (mAFP), are being increasingly used to treat patients with cardiogenic shock resulting from acute myocardial infarction, with trials showing mixed results on their effectiveness.* -
- A comparative analysis of mortality rates from the DanGer-SHOCK and ECLS-SHOCK trials revealed that the mAFP strategy correlated with a notable reduction in mortality at both 30 days and 6 months, suggesting it provides significant benefits over standard care.* -
- The findings indicate that the DanGer unloading strategy, particularly when combined with percutaneous coronary intervention, enhances long-term survival in patients experiencing cardiogenic shock, although further research is necessary to validate these results across diverse patient groups
Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial.
JAMA Cardiol
October 2024
Department of Cardiology, Odense University Hospital, Odense, Denmark.
Importance: Mechanical circulatory support with a microaxial flow pump (MAFP) has been shown to improve survival in ST-elevation myocardial infarction-induced cardiogenic shock (STEMI-CS). Understanding the impact on hemodynamic stability over time is crucial for optimizing patient treatment.
Objective: To determine if an MAFP reduces the need for pharmacological circulatory support without compromising hemodynamics compared with standard care in STEMI-CS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!